<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Macular <z:hpo ids='HP_0000969'>edema</z:hpo> (ME) and <z:mp ids='MP_0005546'>choroidal neovascularization</z:mp> (CNV) can complicate the course of several inflammatory chorioretinal diseases, leading to a severe visual function impairment </plain></SENT>
<SENT sid="1" pm="."><plain>The most frequently involved clinical entities include for example multifocal <z:mp ids='MP_0001848'>choroiditis</z:mp>, <z:e sem="disease" ids="C0339403" disease_type="Disease or Syndrome" abbrv="">presumed ocular histoplasmosis syndrome</z:e>, Be√ßhet's disease, <z:e sem="disease" ids="C0730322" disease_type="Disease or Syndrome" abbrv="MEWDS">multiple evanescent white dot syndrome</z:e>, birdshot <z:hpo ids='HP_0001145'>chorioretinopathy</z:hpo>, <z:hpo ids='HP_0011009'>acute</z:hpo> multifocal posterior placoid pigment epitheliopathy, serpiginous <z:mp ids='MP_0001848'>choroiditis</z:mp>, and persistent placoid <z:e sem="disease" ids="C0730362" disease_type="Disease or Syndrome" abbrv="">maculopathy</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Results that have reported on antivascular endothelial growth factor (anti-VEGF) treatment in uveitic patients with CNV or ME have demonstrated positive results in many cases </plain></SENT>
<SENT sid="3" pm="."><plain>However, bearing in mind that it has been proven impossible to perform randomized clinical trials with anti-VEGF in uveitic patients with CNV or ME, further studies with longer follow-ups are necessary to assess the value of this therapeutic approach </plain></SENT>
</text></document>